Stock comparison
Celldex Therapeutics, Inc. is 1.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($3.06 B vs $2.16 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
CLDX is larger
Celldex Therapeutics, Inc. is 1.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($3.06 B vs $2.16 B).
Market value leader
CLDX
Celldex Therapeutics, Inc. is 1.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($3.06 B vs $2.16 B).
Revenue leader
NTLA
NTLA: $67.67M vs CLDX: $1.54M.
Profit leader
CLDX
NTLA: -$412.69M vs CLDX: -$258.76M.
Margin leader
NTLA
NTLA: -609.9% vs CLDX: -16748.0% net margin.
| Metric | NTLA | CLDX |
|---|---|---|
| Market cap | $2.16 B | $3.06 B |
| US-listed rank | #2076 | #1809 |
| Revenue (latest FY) | $67.67M | $1.54M |
| Net income (latest FY) | -$412.69M | -$258.76M |
| Net margin | -609.9% | -16748.0% |
| P/E (trailing FY) | - | - |
| SEC filings | 679 | 1,268 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Celldex Therapeutics, Inc. is 1.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($3.06 B vs $2.16 B).
In their latest fiscal years, Intellia Therapeutics, Inc. reported $67.67M in revenue while Celldex Therapeutics, Inc. reported $1.54M.
Full pages: Intellia Therapeutics, Inc. and Celldex Therapeutics, Inc., or browse the full rankings.